Skip to content
ClinicalGLP-1 receptor agonist for appetite suppression

Semaglutide

Also indexed as Ozempic, Wegovy, Rybelsus

A GLP-1 receptor agonist approved for type 2 diabetes management and chronic weight management, demonstrating substantial and sustained weight reduction in large clinical trials.

Overview

Activates GLP-1 receptors in pancreas, brain, and gut to regulate glucose and hunger.

Proposed mechanism

Mimics endogenous glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas, brain, and gut. Increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling.

What the evidence supports

Randomised controlled trial data in humans exists and supports use in specific contexts.

Graded Clinical

Findings supported by randomised, controlled trials in humans, with pre-registered endpoints and published results.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Semaglutide for weight loss

    · DOI:10.1056/NEJMoa2032183 · 2021

  2. [2]

    GLP-1 receptor agonists

    · DOI:10.2337/dci19-0034 · 2019

  3. [3]

    Wilding et al. — Semaglutide 2.4 mg for obesity (STEP 1 trial)

    · · 0

  4. [4]

    Marso et al. — Semaglutide cardiovascular outcomes (SUSTAIN-6)

    · · 0

  5. [5]

    Rubino et al. — STEP 4 trial: sustained weight loss

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic

AOD-9604

Anecdotal

HGH fragment for lipolysis stimulation

HGH fragment for localized fat metabolism.

0 RCT · 0 human · 0 preclinical

fat-loss